EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A
For the development of safe and effective EBV (Epstein-Barr virus) vaccines, the Ag85A signal peptide from M. tuberculosis H37Rv was used to construct a recombinant secretory BCG (Bacillus Chalmette-Guérin) plasmid. The Ag85A gene, fused to the EBV LMP2A (latent membrane protein) and hGM-CSF (human...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2020-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b8582372f3f4440abcd18a1ca55f4543 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yingchun Yan |e author |
| 700 | 1 | 0 | |a Qing-Jie Xue |e author |
| 700 | 1 | 0 | |a Ang Liu |e author |
| 700 | 1 | 0 | |a Hui Wang |e author |
| 700 | 1 | 0 | |a Honghua Zhang |e author |
| 700 | 1 | 0 | |a Shuang Wang |e author |
| 700 | 1 | 0 | |a Longyu Zhao |e author |
| 700 | 1 | 0 | |a Yunqing Li |e author |
| 700 | 1 | 0 | |a Xiuzhen Li |e author |
| 700 | 1 | 0 | |a Yuanyuan Yang |e author |
| 700 | 1 | 0 | |a Ting Chen |e author |
| 700 | 1 | 0 | |a Shigen Li |e author |
| 245 | 0 | 0 | |a EB virus-positive tumors are inhibited by rBCG expressing hGM-CSF and LMP2A |
| 260 | |b Taylor & Francis Group, |c 2020-03-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2019.1670593 | ||
| 520 | |a For the development of safe and effective EBV (Epstein-Barr virus) vaccines, the Ag85A signal peptide from M. tuberculosis H37Rv was used to construct a recombinant secretory BCG (Bacillus Chalmette-Guérin) plasmid. The Ag85A gene, fused to the EBV LMP2A (latent membrane protein) and hGM-CSF (human granulocyte/macrophage colony-stimulating factor) genes, was inserted into the pMV261 vector (secretory BCG plasmid). The expression levels of the hGM-CSF and LMP2A proteins in rBCG (recombinant BCG) were measured by Western blot analysis. Humoral immunity, cellular immunity, and antitumor effects were determined by a series of experiments. The recombinant pMVGCA plasmid effectively expressed GCA (hGM-CSF and LMP2A fusion protein) in BCG after transformation, and the rBCG proteins were recognized by antibodies against hGM-CSF and LMP2A. Six weeks after immunization, the maximum dose of rBCG resulted in antibody titers of 1:19,800 (hGM-CSF antibody) and 1:21,800 (LMP2A antibody). When the effector:target ratio was 40:1, specific lysis was maximal and approximately two times stronger than that in mice immunized with the control. Tumorigenicity was lower in the rBCG treatment group, with a tumor inhibition rate of 0.81 ± 0.09 compared with the control groups. EB virus-positive tumors are inhibited by rBCG expressing an hGM-CSF and LMP2A fusion protein. | ||
| 546 | |a EN | ||
| 690 | |a lmp2a | ||
| 690 | |a hgm-csf | ||
| 690 | |a epstein-barr virus | ||
| 690 | |a cytotoxic lymphocyte | ||
| 690 | |a mice | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 16, Iss 3, Pp 654-663 (2020) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2019.1670593 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/b8582372f3f4440abcd18a1ca55f4543 |z Connect to this object online. |